Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Lexicon Pharmaceuticals Inc shares valued at $480,000 were purchased by COATS LONNEL on Aug 15 ’24. At $1.60 per share, COATS LONNEL acquired 300,000 shares.
As published in their initiating research note from H.C. Wainwright on June 17, 2024, Lexicon Pharmaceuticals Inc [LXRX] has been a Buy and the price target has been revised to $10. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in late April. As of March 07, 2023, Jefferies has initiated its “Hold” rating for LXRX. Earlier on August 12, 2022, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for LXRX stock.
Analyzing LXRX Stock Performance
During the last five days, there has been a surge of approximately 26.49%. Over the course of the year, Lexicon Pharmaceuticals Inc shares have dropped approximately -46.26%. Shares of the company reached a 52-week high of $3.7300 on 02/16/24 and a 52-week low of $0.6204 on 12/05/24. A 50-day SMA is recorded $1.3065, while a 200-day SMA reached $1.7304. Nevertheless, trading volume fell to 8.41 million shares from 15.65 million shares the previous day.
Support And Resistance Levels for Lexicon Pharmaceuticals Inc (LXRX)
According to the 24-hour chart, there is a support level at 0.7423, which, if violated, would cause prices to drop to 0.6625. In the upper region, resistance lies at 0.9397. The next price resistance is at 1.0573. RSI (Relative Strength Index) is 40.95 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0404, which suggests the price will decrease in the coming days. Percent R is at 49.50%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
